WO1998038283A1 - Procedes de selection de cellules competentes de lignees germinales dans des embryons de poulets et utilisation de ces cellules dans la production de chimeres - Google Patents

Procedes de selection de cellules competentes de lignees germinales dans des embryons de poulets et utilisation de ces cellules dans la production de chimeres Download PDF

Info

Publication number
WO1998038283A1
WO1998038283A1 PCT/CA1998/000145 CA9800145W WO9838283A1 WO 1998038283 A1 WO1998038283 A1 WO 1998038283A1 CA 9800145 W CA9800145 W CA 9800145W WO 9838283 A1 WO9838283 A1 WO 9838283A1
Authority
WO
WIPO (PCT)
Prior art keywords
germ
cells
embryo
competent cells
line
Prior art date
Application number
PCT/CA1998/000145
Other languages
English (en)
Inventor
Robert J. Etches
Original Assignee
University Of Guelph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Guelph filed Critical University Of Guelph
Priority to AU60848/98A priority Critical patent/AU6084898A/en
Priority to JP53710598A priority patent/JP2001516206A/ja
Priority to CA002282791A priority patent/CA2282791A1/fr
Priority to EP98905172A priority patent/EP0973870A1/fr
Publication of WO1998038283A1 publication Critical patent/WO1998038283A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells

Definitions

  • the invention relates to methods for selecting germ-line competent cells, and methods for producing germ-line chimeras in avian species.
  • BACKGROUND OF THE INVENTION The poultry industry has traditionally relied on crossbreeding of pure lines to provide chickens, turkeys and other poultry with desirable characteristics. The genetic rearrangement that occurs at each generation usually results in offspring that bear only a small proportion of the attributes of superior individuals in the parental population. Ideally, breeders would like more control over the manipulation of the genome.
  • the methods are expensive since the avian species must be killed to obtain each ovum or zygote; it is difficult to identify the male and female pronuclei among the supemumary spermatozoa that enter at fertilization; exogenous DNA does not integrate into the genome at a high rate when injected into newly fertilized zygotes; and it is technically difficult to return the manipulated ovum to the oviduct of a fistulated hen, or to maintain it in a surrogate egg. Therefore, more current methods involve the manipulation of blastodermal cells contained in the newly laid egg. Fertilization of chicken embryos occurs within 15 minutes following ovulation in the infundibulum of the reproduction tract.
  • the embryo which is situated on the surface of the yolk, develops during the next 18-23 hours as egg formation is completed by the secretion of albumen, membranes and shell around the yolk.
  • the first cell division occurs approximately 5 hours after fertilization as the egg enters the shell gland.
  • embryonic divisions continue rapidly to yield an embryo containing 40,000 - 60,000 cells (Eyal-Giladi & Kochav, 1976; Kochav et al, 1980; Watt et al, 1993).
  • the embryonic structure which contains 40,000-60,000 cells is designated as a stage X (E-G & K) embryo.
  • stage X (E-G & K) embryos The production of somatic and germ-line chimeras after the injection of cells from stage X (E-G & K) embryos may indicate that each cell in a stage X (E-G & K) embryo can contribute to ectoderm, mesoderm, endoderm and the germ-line and, therefore, each cell from a stage X (E-G & K) embryo is pluripotent.
  • stage X (E-G & K) embryos contains cells with different functional properties.
  • the EMA-1 epitope which is believed to be expressed uniquely on primordial germ cells which are committed to the germ-line, is expressed on some cells in stage XI (E-G & K) embryo (Urven et al., 1988; Karagenc et al, 1995).
  • the epitope SSEA-1 which is expressed by mouse embryonic stem cells, is expressed by some cells in stage XIII (E- G&K) embryos (Petitte and Karagenc, 1996).
  • E-G&K morphologically unrecognizable primordial germ cells in stage X
  • embryos may be inferred from the presence of committed primordial germ cells in cultures derived from the central disc, but not the area opaca, of stage X blastoderms (Ginsburg and Eyal- Giladi, 1987).
  • the presence of cells that are destined for the germ-line can also be inferred from the observation that somatic and germ-line chimeras are produced more frequently from cells taken from the central disc rather than the area opaca of stage X (E-G&K) embryos (Petitte et al., 1993).
  • the QH-1 epitope which is believed to be expressed by cells committed to the germ-line in quail, is expressed in embryonic cells at the time of oviposition (Pardanaud et al., 1987).
  • stage X E- G&K
  • chimeric avian species such as chickens would be greatly enhanced if the location of germ-line competent cells within stage X (E-G&K) embryos were identified, and if populations of germ-line committed cells could be isolated from the entire population of cells that comprise a stage X (E-G&K) embryo.
  • E-G&K stage X
  • the endogenous contribution is reduced, but not eliminated, by irradiating the recipient embryo (Carsience et al., 1993).
  • Irradiation impedes growth of the recipient embryo for approximately 24 hours while the donor-derived contributions to the chimera proliferate (Carsience et al., 1993). While this approach has proved to be useful, the extent of the donor-derived contribution to the germ-line is neither predictable nor consistent. The lack of a predictable and consistent contribution to the germ-line is particularly important when the donor-cell population contains a small number of genetically unique and rare donor cells. Examples of rare cells might include genetically modified cells (see Brazolot et al., 1991; Fraser et al., 1993) or cells derived from cryopreserved stocks that are extinct (see Kino et al., 1997).
  • chimeric chickens would also be enhanced if cell surface epitopes expressed by germ-line competent cells within stage X (E-G&K) embryos were identified. The identification of the epitopes would facilitate development of methods to identify and isolate germ-line competent cells.
  • the present inventor has identified cell surface epitopes expressed by germ- line competent cells within stage X(E-G&K) embryos of chickens.
  • the present inventor has identified the EMA-1 and SSEA-1 epitopes in stage X (E-G & K) chicken embryos and in cells derived from them in culture.
  • the identification of the epitopes facilitated the identification and isolation of cells within stage X (E-G&K) chicken embryos that are capable of replication without differentiation in vitro and which retain the ability to enter the germ-line following injection into a recipient embryo.
  • germ-line competent cells Isolated germ-line competent cells from donor embryos were introduced into recipient embryos to produce chimeric embryos.
  • the present invention relates to a method for selecting germ- line competent cells in stage X (E-G&K) chicken embryos comprising separating from a stage X (E-G&K) chicken embryo cells that have an epitope expressed by germ-line competent cells associated with their cell surface.
  • germ-line competent cells may be isolated by reacting cells obtained from a stage X (E-G&K) chicken embryo with a substance which binds directly or indirectly to an epitope expressed by germ-line competent cells.
  • the epitope expressed by germ-line competent cells is an EMA-1 or an SSEA-1 epitope.
  • the invention also relates to a method for producing a cell preparation enriched for germ-line competent cells of chickens comprising (a) providing cells from a stage X (E-G&K) chicken embryo; and (b) selecting cells that have an epitope expressed by germ-line competent cells associated with their cell surface.
  • Germ-line competent cells identified and isolated using the methods of the invention may be genetically modified by introducing a recombinant expression vector into the cells. Therefore, the methods of the invention may additionally comprise transfecting the germ-line competent cells with a recombinant expression vector containing an exogenous gene and the necessary elements for the transcription and translation of the gene.
  • the invention additionally relates to a cell culture comprising germ-line competent cells or genetically modified germ-line cells obtained using the methods of the invention.
  • the invention still further relates to a method for identifying a region in an embryo which contains germ-line competent cells comprising
  • the epitope expressed by germ-line competent cells is an EMA-1 or an SSEA-1 epitope and the substance that binds to the epitope is an antibody.
  • the germ-line cells identified in accordance with the methods of the invention may be used to produce chimeric chicken embryos. Therefore, the present invention provides a method for producing a chimeric chicken embryo comprising (a) isolating from a donor stage X (E-G&K) chicken embryo cells that have an epitope expressed by germ-line competent cells associated with their cell surface; (b) optionally transfecting the cells with a recombinant expression vector containing an exogenous gene and the necessary elements for the transcription and translation of the gene; (c) introducing the cells into a recipient stage X (E-G&K) chicken embryo from which a portion of the central disk of the embryo has been removed; and (d) incubating the recipient embryo to produce a chimeric embryo.
  • the chimeric embryo may be grown to term to produce chimeric chickens.
  • the invention further provides chimeric embryos and chimeric chickens produced by the methods of the invention.
  • kits for performing the methods of the invention relate to kits for performing the methods of the invention.
  • Figure 1 shows the structure of a stage X embryo illustrated as a cross-section through the embryo perpendicular to the surface of the yolk;
  • Figure 2 shows a phase contrast illumination micrograph illustrating the expression of EMA-1 epitopes on stage X blastodermal cells.
  • Figure 3 shows a fluorescence micrograph of Figure 2
  • Figure 4 shows a phase contrast illumination micrograph illustrating the expression of SSEA-1 epitopes on stage X blastodermal cells
  • Figure 5 shows a fluorescence micrograph of Figure 4.
  • Figure 6 shows a phase contrast illumination micrograph illustrating the SSEA-1 expression on stage X whole mount
  • Figure 7 shows a fluorescence micrograph of Figure 6;
  • Figure 8 shows a phase contrast illumination micrograph illustrating HNK-
  • Figure 9 shows a fluorescent micrograph of Figure 8. DETAILED DESCRIPTION OF THE INVENTION I. Selection of Germ-line Competent Cells
  • the present invention relates to a method for selecting germ-line competent cells in stage X (E-G&K) chicken embryos comprising separating from a stage X (E-G&K) chicken embryo, cells which have an epitope expressed by germ-line competent cells associated with their cell surface.
  • the invention also relates to a method for producing a cell preparation enriched for germ-line competent cells of chickens comprising (a) providing cells from a stage X (E-G&K) chicken embryo; and (b) selecting cells that have an epitope expressed by germ-line competent cells associated with their cell surface.
  • the epitope expressed by germ-line competent cells is an EMA-1 or an SSEA-1 epitope.
  • a stage X (E-G&K) chicken embryo is an embryo which is expelled from the shell gland at oviposition and it is characterized by containing between 40,000 - 60,000 cells (Eyal-Giladi & Kochav, 1976; Kochav et al., 1980; Watt et al, 1993).
  • the architecture of a stage X (E-G & K) embryo is illustrated in Figure 1. Morphologically, none of the cells in a stage X embryo demonstrate the characteristics of differentiated cells.
  • the central disc which includes the area pellucida and the marginal zone, is surrounded by the area opaca.
  • the area pellucida is situated above a layer of subgerminal fluid that separates the embryo from the underlying yolk.
  • the area opaca is directly in contact with the surrounding yolk.
  • Stage X (E-G&K) embryos may be isolated from eggs using conventional methods, For example, embryos may be isolated from freshly laid unincubated eggs by separating albumen from the yolk as described by Carsience et al (1993)
  • cells from a stage X (E- G&K) chicken embryo are preferably dissociated from the embryo using conventional techniques
  • blastoderm cells may be dispersed from an embryo by treating with a substance which digests the extracellular matrix such as trypsin.
  • the invention provides a method for selecting germ-line competent cells in stage X chicken embryos comprising reacting cells obtained from a stage X (E-G &K) chicken embryo with one or more antibodies to an epitope expressed by germ-line competent cells; forming conjugates between the antibodies and the germ-line competent cells having the epitope associated with their cell surface; and isolating the conjugates to obtain a cell preparation containing germ-line competent cells.
  • the method may employ more than one antibody, for example one antibody to EMA-1 and one antibody to SSEA-1.
  • antibody includes polyclonal antisera or monoclonal antibodies. Conventional methods can be used to prepare the antibodies. For example, by using a EMA- 1 and SSEA-1 epitope, polyclonal antisera or monoclonal antibodies can be made using standard methods. A mammal, (e.g., a mouse, hamster, or rabbit) can be immunized with an immunogenic form of a EMA-1 or SSEA-1 epitope which elicits an antibody response in the mammal. Techniques for conferring immunogenicity on an epitope include conjugation to carriers or other techniques well known in the art. The progress of immunization can be monitored by detection of antibody titers in plasma or serum.
  • Standard ELISA or other immunoassay procedures can be used with the immunogen as antigen to assess the levels of antibodies.
  • antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.
  • antibody producing cells lymphocytes
  • myeloma cells can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells.
  • Such techniques are well known in the art, [e.g., the hybridoma technique originally developed by Kohler and Milstein (Nature 256, 495-497 (1975)]. Other techniques such as screening of combinatorial antibody libraries can be employed (Huse et al., Science 246, 1275 (1989)].
  • Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with the epitopes and the monoclonal antibodies can be isolated.
  • antibody also includes antibody fragments which also specifically react with an epitope expressed by germ-line competent cells. Antibodies can be fragmented using conventional techniques and the fragments screened for utility as described above. For example, F(ab') 2 fragments can be generated by treating antibody with pepsin. The resulting F(ab') 2 fragment may be treated to reduce disulfide bridges to produce
  • Chimeric antibody derivatives i.e., antibody molecules that combine a non- avian variable region and an avian constant region are also within the scope of the invention.
  • Chimeric antibody molecules include, for example, the antigen binding domain from an antibody of a mouse, rat, or other species, with avian constant regions.
  • Standard methods may be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes an epitope expressed by germ-line competent cells (See, for example, Morrison et al., Proc. Natl Acad. Sci. U.S.A. 81,6851 (1985); Takeda et al., Nature 314, 452 (1985), Cabilly et al, U.S. Patent No.
  • binding partners may be constructed utilizing recombinant DNA techniques to incorporate the variable regions of a gene which encodes a specifically binding antibody.
  • the genes which encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using nucleotide primers for the variable region. These primers may be synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources. The primers may be utilized to amplify heavy or light chain variable regions, which may then be inserted into vectors such as ImmunoZAPTM H or ImmunoZAPTM L (Stratacyte), respectively. These vectors may then be introduced into E. coli for expression. Utilizing these techniques, large amounts of a single-chain protein containing a fusion of the V H and
  • V L domains may be produced (See Bird et al, Science 242:423-426, 1988).
  • Antibodies against an epitope may also be obtained from commercial sources.
  • monoclonal antibodies to SSEA-1 and EMA-1 may be obtained from Immunotech, Westbrook, ME, USA.
  • the antibodies may be labelled with a detectable marker including various enzymes, fluorescent materials, luminescent materials and radioactive materials.
  • suitable enzymes include horseradish peroxidase, biotin, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent material includes luminol;
  • suitable radioactive material include S-35, Cu-64, Ga-67, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-Ill, 1-123, 1-125, 1131, Re-186, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212.
  • the antibodies may also be labelled or conjugated to one partner of a ligand binding pair.
  • Representative examples include avidin-biotin and riboflavin-riboflavin binding protein.
  • Methods for conjugating or labelling the antibodies with the representative labels set forth above may be readily accomplished using conventional techniques.
  • the antibodies may be labelled with a detectable marker as described herein or indirect methods may be employed. In an indirect method, the primary antigen-antibody reaction may be amplified by the introduction of a second antibody, having specificity for the antibody reactive against an epitope.
  • the antibody having specificity against an EMA-1 or SSEA-1 epitope is a mouse IgG antibody
  • the second antibody may be rat or rabbit anti-mouse gamma-globulin labelled with a detectable marker as described herein.
  • the antibodies may be bound to a carrier such as agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose polystyrene, filter paper, ion-exchange resin, plastic film, plastic tube, glass beads, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc.
  • the carrier may be in the shape of, for example, a tube, test plate, beads, disc, sphere etc.
  • the antibodies may be conjugated to a matrix.
  • matrices are magnetic beads, which allow for direct magnetic separation (Kernshead 1992), panning surfaces e.g. plates, (Lebkowski, J.S, et al., (1994), J. of Cellular Biochemistry supple. 18b:58), dense particles for density centrifugation (Van Vlasselaer, P., Density Adjusted Cell Sorting (DACS), A Novel Method to Remove Tumor Cells From Peripheral Blood and Bone Marrow StemCell Transplants.
  • the antibodies may also be joined to a cytotoxic agent such as complement or a cytotoxin, to lyse or kill the targeted germ-line competent cells.
  • a cytotoxic agent such as complement or a cytotoxin
  • the antibodies may be directly coupled to a matrix.
  • the antibodies may be chemically bound to the surface of magnetic particles for example, using cyanogen bromide.
  • conjugates will form between the magnetic particles with bound antibodies and the germ-line competent cells.
  • the antibodies may be indirectly conjugated to a matrix using antibodies.
  • a matrix may be coated with a second antibody having specificity for the antibodies to a SSEA-1 or an EMA-1 epitope.
  • the antibodies to the SSEA-1 or EMA-1 epitope are mouse IgG antibodies
  • the second antibody may be rabbit anti-mouse IgG.
  • the antibodies may also be incorporated in antibody reagents which indirectly conjugate to a matrix. Examples of antibody reagents are bispecific antibodies, tetrameric antibody complexes, and biotinylated antibodies.
  • Bispecific antibodies contain a variable region of an antibody specific for an epitope expressed by germ-line competent cells, and a variable region specific for at least one antigen on the surface of a matrix.
  • the bispecific antibodies may be prepared by forming hybrid hybridomas.
  • the hybrid hybridomas may be prepared using the procedures known in the art such as those disclosed in Staerz & Bevan, (1986, PNAS (USA) 83: 1453) and Staerz & Bevan, (1986, Immunology Today, 7:241).
  • Bispecific antibodies may also be constructed by chemical means using procedures such as those described by Staerz et al., (1985, Nature, 314:628) and Perez et al., (1985 Nature 316:354), or by expression of recombinant immunoglobulin gene constructs.
  • a tetrameric immunological complex may be prepared by mixing a first monoclonal antibody which is capable of binding to at least one antigen on the surface of a matrix, and a second monoclonal antibody specific for an epitope expressed by germ-line competent cells.
  • the first and second monoclonal antibody are from a first animal species.
  • the first and second antibody are reacted with an about equimolar amount of monoclonal antibodies of a second animal species which are directed against the Fc-fragments of the antibodies of the first animal species.
  • the first and second antibody may also be reacted with an about equimolar amount of the F(ab') 2 fragments of monoclonal antibodies of a second animal species which are directed against the Fc-fragments of the antibodies of the first animal species.
  • the antibodies may be biotinylated and indirectly conjugated to a matrix which is labelled with (strept) avidin.
  • strept a matrix which is labelled with (strept) avidin.
  • biotinylated antibodies may be used in combination with magnetic iron-dextran particles that are covalently labelled with (strept) avidin (Miltenyi, S. et al., Cytometry 11:231, 1990).
  • Many alternative indirect ways to specifically cross-link the antibodies and matrices would also be apparent to those skilled in the art.
  • the cell-antibody conjugates are removed by magnetic separation using magnetic particles.
  • Suitable magnetic particles include particles in ferrofluids and other colloidal magnetic solutions. Examples of ferrofluids and methods for preparing them are described by Kemshead J.T. (1992) in J. Hematotherapy, 1:35-44, at pages 36 to 39, and Ziolo et al. Science (1994) 257:219 which are incorporated herein by reference. Colloidal particles of dextran-iron complex may be used in the process of the invention. (See Molday, R.S. and McKenzie, L.L. FEBS Lett.
  • Magnetic particles may also be obtained from commercial sources such as the microbeads available from Mitenyi Biotec.
  • a sample containing germ-line competent cells to be recovered is reacted with one of the above described antibody reagents so that the antibody reagents bind to the targeted germ-line competent cells present in the sample to form cell conjugates of the targeted cells and the antibody reagents.
  • the reaction conditions are selected to provide the desired level of binding between the targeted cells and the antibody reagents.
  • the concentration of the antibody reagents is selected depending on the estimated concentration of the targeted cells in the sample.
  • the magnetic particles are then added and the mixture is incubated at the selected temperature.
  • the sample is then ready to be separated over a magnetic filter device.
  • the magnetic separation procedure is carried out using the magnetic filter and methods described in Miltenyi et al, 1990. Commercial magnetic separation systems such as the MiniMACS system available from Miltenyi Biotch may also be used in the magnetic separation methods of the present invention.
  • the sample containing the magnetically labelled cell conjugates is passed through the magnetic filter in the presence of a magnetic field.
  • the magnetically labelled conjugates are retained in the high gradient magnetic column and the materials which are not magnetically labelled flow through the column after washing with a buffer.
  • Antibodies to an epitope expressed by germ-line competent cells may also be used to detect and quantify germ-line competent cells in an embryo.
  • the antibodies may be used in immuno-histochemical analyses to localise germ-line competent cells to particular regions in the embryo.
  • Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect germ-line competent cells.
  • an antibody labelled with a detectable marker can be used to localize the germ-line competent cells in an embryo based upon the presence of the detectable marker.
  • Antibodies may also be coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.
  • the reagents suitable for applying the methods of the invention may be packaged into convenient kits providing the necessary materials, packaged into suitable containers.
  • kits may include all the reagents required to select a germ-line competent cell in a sample by means of the methods described herein, and optionally suitable supports useful in performing the methods of the invention.
  • Germ-line competent cells isolated from stage X (E-G&K) embryos in accordance with the methods of the invention may be genetically modified by random or site-directed integration of DNA into the cells. Therefore, the present invention relates to the genetic modification of germ-line competent cells isolated by the methods of the invention comprising introducing a recombinant expression vector containing an exogenous gene and the necessary elements for the transcription and translation of the gene.
  • exogenous genes which can be introduced into the germ-line competent cells include vasoactive intestinal peptide, growth hormone, insulin-like growth factor I, the IGF-I receptor, the GH receptor, prolactin, the gonadotrophins, and gonadotrophin-releasing hormone (Etches et al, 1993 and references therein). Selection of the necessary elements for the transcription and translation of the genes may be readily accomplished by one of ordinary skill in the art.
  • the necessary regulatory sequences may be supplied by the native genes and /or their flanking regions.
  • Transfer of DNA into the germ-line cells may be accomplished using retroviral vectors (Shuman, Experientia, 47:897-904, 1991; Petropoulos et al., Journal of Virology, 66:3391-3397, 1992; Salter et al, Manipulation of the Avian Genome, pp. 135-150, 1993).
  • Large DNA sequences greater than 2000 base pairs, including those designed to promote specific integration within the genome via homologous recombination, can be introduced by liposome-mediated gene transfer.
  • Genetically modified germ-line competent cells can be cultured in vitro to provide a population of genetically modified germ-line competent cells.
  • Single germ-line competent cells may also be cloned using conventional techniques to provide a homogenous population of genetically modified donor cells.
  • the germ-line competent cells selected using the methods of the invention may be used to produce chimeric chicken embryos.
  • Chimeric chicken embryos are produced by isolating from a donor stage X (E-G&K) chicken embryo using the methods described herein, germ-line competent cells that have an epitope expressed by germ-line competent cells associated with their cell surface.
  • the epitope is EMA-1 or SSEA-1.
  • the isolated germ-line competent cells may be transfected with a recombinant expression vector containing an exogenous gene and the necessary elements for the transcription and translation of the gene as described herein.
  • the germ-line competent cells are introduced into a recipient stage X (E-G&K) chicken embryo from which a portion of the central disk of the embryo has been removed.
  • the cells are introduced using conventional methods such as injection into the subgerminal cavity of the recipient embryo.
  • a portion of the central disk of the recipient embryo is removed using physical techniques, or using antibodies to an epitope conjugated to a toxin or to complement to kill recipient germ-line competent cells
  • recipient embryos Prior to removal of the central disk portion, recipient embryos may optionally be exposed to irradiation (e g 490-680 rads of ⁇ irradiation from a 60 Co source) After mtroduction of the donor germ-lme competent cells mto the recipient embryo, the recipient embryo is mcubated to produce a chimeric embryo
  • the recipient embryos contammg the donor germ-lme competent cells may be transferred preferably on the fourth day of development, mto surrogate culture systems, to provide the appropriate environment to support development of a chicken embryo from syngamy to hatchmg Suitable surrogate culture systems are described m Etches et al, (1996b)
  • the methods described herem improve the rate of transmission of the donor cell line to the recipient and provide larger numbers of chimeras This facilitates commercial breeding programs to replace pure lines by genetically superior lines
  • the invention provides the isolation and identification of molecules (including genes and protems) that are associated with germ-lme cells Such germ-lme specific molecules can be used as markers to identify and separate germ-lme cells from a population of cells using the methods of the present invention
  • the germ-lme specific molecules can be isolated usmg a variety of techniques known in the art Methods to detect germ-lme specific molecules mclude digestion of the germ-line cells with restriction endonucleases followed by analysis of the resultmg fragments, differential hybridization of ohgonucleotides, direct PCR sequencing, differential hybridization of ohgonucleotides and denaturing gradient gel electrophoresis
  • germ-lme specific molecule can be detected by the differential hybridization of ohgonucleotides
  • germ-lme cells can be isolated usmg the methods of the mvention and the messenger RNA mav be obtamed from the cells
  • a cDNA library may be constructed from mRNA prepared from a pool of control cells
  • cDNA libraries may be synthetized usmg Ohgo-dT primers and reverse transc ⁇ ptase according to standard protocols
  • cDNA may be cloned mto plasmid vectors such as pSPORT R (Gibco BRL)
  • cDNA libraries may also be used such as phage display random libraries
  • the germ-line cell mRNA can be used to probe a library for sequences that specifically hybridize to the mRNA from the germ-lme cells but not to mRNA isolated from control cells
  • Hybridization conditions which may be used m the methods of the mvention are known in the art and are described for example m Sambrook J, F ⁇ tch EF, Maruatis T In- Molecular Cloning, A Laboratory Manual, 1989. (Nolan C, Ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, which is incorporated herein by reference.
  • the hybridization product may be assayed using techniques known in the art.
  • subtractive hybridization can also be used.
  • Subtractive hybridization can identify and enrich genes that are differentially expressed in germ-line competent cells.
  • Subtractive hybridization can be carried out by hybridizing between two DNA (or RNA) populations that are closely related such as the germ-line competent cells of the invention and other cells present in the stage X embryos.
  • the hybridized sequences common to both cell types can be removed.
  • the unhybridized sequences can be preserved as a subtracted cDNA library.
  • Subtractive hybridization techniques known in the art can be used for example Christian E.
  • germ-line specific molecules could be detected using denaturing gradient gels. Restriction endonuclease fragments or PCR fragments associated with a selected nucleotide segment of germ-line specific cells can be resolved on a polyacrylamide gel containing gradients of denaturants, such as increasing temperature, increasing formamide, urea, and the like. The germ-line specific cell fragment and control fragments will denature at different positions in the gel leading to altered migration distances. The resolved fragments can the be detected by DNA hybridization for restriction fragments or direct DNA straining for PCR fragments.
  • the present invention provides a method of detecting germ-line specific molecules using any of the above methods. Regulatory sequences such as promoters that control expression of the germ- line specific molecules may also be isolated.
  • Identification of germ-line specific molecules of the invention also permits the identification and isolation, or synthesis of nucleotide sequences which may be used as primers to amplify a nucleic acid molecule of the invention, for example in the polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the present invention includes a method of determining the presence of a germ-line specific nucleic acid molecule of the invention is provided comprising treating the sample with primers which are capable of amplifying the nucleic acid molecule or a predetermined oligonucleotide fragment thereof in a polymerase chain reaction to form amplified sequences, under conditions which permit the formation of amplified sequences and, assaying for amplified sequences.
  • the polymerase chain reaction refers to a process for amplifying a target nucleic acid sequence as generally described in Innis et al, Academic Press, 1990 in Mullis el al, U.S. Pat. No. 4,863,195 and Mullis, U.S. Patent No. 4,683,202 which are incorporated herein by reference.
  • Conditions for amplifying a nucleic acid template are described in M.A. I nis and D.H. Gelfand, PCR Protocols, A Guide to Methods and Applications M.A. Innis, D.H. Gelfand, J.J. Sninsky and T.J. White eds, pp3-12, Academic Press 1989, which is also incorporated herein by reference.
  • the amplified products can be isolated and distinguished based on their respective sizes using techniques known in the art. For example, after amplification, the DNA sample can be separated on an agarose gel and visualized, after staining with ethidium bromide, under ultra violet (UW) light. DNA may be amplified to a desired level and a further extension reaction may be performed to incorporate nucleotide derivatives having detectable markers such as radioactive labelled or biotin labelled nucleoside triphosphates. The primers may also be labelled with detectable markers as discussed above. The detectable markers may be analyzed by restriction and electrophoretic separation or other techniques known in the art. The conditions which may be employed in the methods of the invention using
  • PCR are those which permit hybridization and amplification reactions to proceed in the presence of DNA in a sample and appropriate complementary hybridization primers.
  • Conditions suitable for the polymerase chain reaction are generally known in the art. For example, see M.A. Innis and D.H. Gelfand, PCR Protocols, A guide to Methods and Applications, M.A. Innis, D.H. Gelfand, J.J. Sninsky and T.J. White eds, pp3-12, Academic Press 1989, which is incorporated herein by reference.
  • the PCR utilizes polymerase obtained from the thermophilic bacterium Thermus aquatics (Taq polymerase, GeneAmp Kit, Perkin Elmer Cetus) or other thermostable polymerase may be used to amplify DNA template strands. It will be appreciated that other techniques such as the Ligase Chain
  • RNA may be isolated from a cell type or tissue known to express a nucleic acid of the invention and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein.
  • the techniques may be used to detect differences in transcript size which may be due to normal or abnormal alternative splicing.
  • the isolated molecules may be used to prepare antibodies which can be used in the methods of the present invention to select germ-line competent cells. Conventional methods can be used to prepare the antibodies as described in detail above.
  • Donor embryos were obtained from Barred Beverly Rocks that are homozygous recessive (ii) at the I locus.
  • Recipient embryos were obtained from White Leghorns that are homozygous dominant (II) at the I locus.
  • the down colour of the Barred Madison Rocks and White Leghorns are black and yellow, respectively. These phenotypes facilitate determination of chimerism by feather colour when chicks hatch: chicks with black down were designated as somatic chimeras whereas yellow chicks were designated as putative chimeras.
  • the contribution of donor- and recipient-derived cells to the germ-line was estimated by mating chimeras to Barred Plymouth Rocks and the extent of germ-line chimerism was expressed as the ratio of the number of Barred Rock to White Leghorn offspring.
  • Donor cells were obtained from Stage X blastoderms (Eyal-Giladi and Kochav, 1976) isolated from freshly laid, unincubated eggs as described by Carsience et al. (1993). Briefly, the albumen was separated from the yolk, the embryo was isolated, and the blastodermal cells were dispersed by digesting the extracelluar matrix with trypsin. The cells were then washed and resuspended in DMEM (Dulbecco's Modified Eagle's Medium) containing 10% fetal bovine serum (FBS). Between 100 and 500 cells in 2-5 ⁇ l of medium were injected into the subgerminal cavity of recipient embryos.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS fetal bovine serum
  • Recipient embryos were physically compromised by removing a portion of the central disk or removing a portion of the lateral edge of the embryo, and control embryos were left intact. Approximately half of the embryos that were physically compromised and all of the control embryos were exposed to 490-680 rads of g irradiation from a 60 Co source within one hour after oviposition and within 2 h before they were physically compromised.
  • Donor cells were injected into all of the recipient embryos that were irradiated but not physically compromised and approximately one half of the recipient embryos that were physically compromised with or without exposure to irradiation. On the fourth day after injection, the embryos were transferred to surrogate shells and incubated to term as described by Etches et al. (1996b). Preparation of Culture Dishes
  • SNL 76/7 murine fibroblast feeder cells (a gift from A. Bradley, Baylor College of Medicine, Houston, TX, USA) were seeded on 0.1% sterile bovine skin gelatin (Sigma, St. Louis, MO, USA) coated culture dishes (Nunc, Denmark) at a density of 1.25 x 10 5 cells/cm 2 .
  • Feeder cells were maintained in Dulbecco's modified Eagle's medium (DMEM)(Gibco, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum (FBS) (Cansera, Rexdale, ON, Canada), 2mM L-glutamine (Gibco), 100 IU/ml penicillin and lOO ⁇ g/ml streptomycin (Gibco) at pH 7.2 for 24 hours at 37°C in 5% C0 2 .
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • Gibco 2mM L-glutamine
  • Blastoderms were then incubated for 10 minutes on ice.
  • the CMF-PBS was replaced with 0.05% trypsin (w/v) in 0.02% EDTA (w/v) (Gibco) and blastoderms were again incubated for 10 minutes on ice.
  • Trypsin was replaced with 1.0 ml of Opt-modified Eagle's medium I (Optimem) (Gibco) supplemented with 2% ChS, 4% (v/v) FBS, 100 IU/ml penicillin and 100 ⁇ g/ml streptomycin at pH 7.2.
  • the blastoderms were pooled and slowly dispersed by aspiration with a 10 ml pipette.
  • a sample of cell suspension was used to determine cell concentration with a haemocytometer. Dissociated cells were centrifuged for 4 minutes at 1000 rpm. The supernatant was removed and cells were resuspended in an appropriate volume of Optimem. Dispersed blastodermal cells were plated on SNL feeder cells at a concentration of lxlO 5 cells/cm 2 incubated for 1, 3, 7, or 18 hours at 37°C in 5% C0 2 .
  • SSEA-1 and EMA-1 antibody supematants were obtained from the Developmental Studies Hybridoma Bank maintained by the Department of Pharmacology and Molecular Sciences, John Hopkins University School of Medicine, Baltimore, MD, and the Department of Biological Sciences, University of Iowa, Iowa City, IA under contract N01-HD-6-2915 from the NICHD.
  • the preparations were washed two times in PBS-BSA and incubated for 2 hours at 4°C in the dark with affinity-purified goat anti-mouse IgM-FITC conjugate diluted 1:50 (Jackson ImmunoResearch, West Grove, PA, USA).
  • Dissociated cell preparations were incubated with monoclonal antibodies SSEA-1, EMA-1 or NC-1 (Immunotech, Westbrook, ME, USA) for 45 minutes at 4°C. Before incubation, blastodermal cells were isolated as outlined above, except that trypsin was replaced with PBS-ChS. Subsequently, the cell preparation was washed in PBS-BSA and incubated with 100 ⁇ l of PBS-BSA containing rat anti-mouse IgM conjugated microbeads (Miltenyi Biotec, Sunnyvale, CA, USA) for 30 minutes at 4°C. The mixture was then washed again and resuspended in 500 ⁇ l of PBS-BSA.
  • a steelwool separation column (type MS+: Miltenyi Biotech) was inserted into a MiniMACS magnetic system (Miltenyi Biotech) and rinsed with PBS-BSA. The cell suspension was run through the column. Unbound (negative) cells were flushed out with PBS-BSA. Cells labelled with the superparamagnetic beads are magnetic in a magnetic field and bind to the steelwool fibers of the column, while unlabelled cells pass through the column (Miltenyi et al., 1990). Finally, the column was removed from the magnetic field and the bound (positive) cells eluted by rinsing with PBS-BSA. Immunohistochemistry was performed on the cells before and after magnetic cell sorting.
  • somatic and germ-line chimeras that were produced after injection of Barred Neighborhood Rock donor cells into White Leghorn recipient embryos that were compromised by irradiation and extirpation of approximately 500 cells from the central or lateral regions of the embryos are shown in Table 3-6. Somatic chimeras hatch with some black (donor-derived) pigmentation (see column 2 in Table 3-6). Putative chimeras have no black (donor-derived) pigmentation. Previous work from our laboratory has shown that putative chimeras usually are not germ-line chimeras. When embryos were irradiated and approximately 500 cells were injected into the central regions of the embryo (Table 3), 5 of the 9 somatic chimeras produced donor-derived offspring, (i.e.
  • Irradiation of recipient embryos is believed to improve the rate of germ-line chimerism by slowing the rate of development of the recipient embryo. Since the donor cells have not been irradiated, they proliferate while cell division is inhibited in the recipient embryo and consequently, the ratio of donor recipient cells in the chimera is increased (Carsience et al., 1993). Removal of cells from the center of the embryo also increases the ratio of germ-line chimerism (from 0.6% to 11.3%, see Table 7). In this case, the increase is attributed to the removal of germ-line cells from the center of the recipient and the subsequent reintroduction of donor germ-line competent cells to the same area. This interpretation is supported by the very low rate of germ-line transmission that follows removal of cells from the lateral regions of the embryo (Table 7).
  • a three fold enrichment of Stage-X blastodermal cells expressing the SSEA-1 epitope was achieved using SSEA-1 coated microbeads. Immunofluorescence verified that the percentage of SSEA-1 staining cells increased from 14% to 45% after separation. Immunomagnetic isolation of EMA-1 positive cells resulted in a three fold enrichment from 8% of the cells before purification to 28% after purification. Selection for cells expressing NC-1 epitopes resulted in a two fold increase. The percentage of NC-1 positive cells increased from 48% to 89% after separation. In all cases, viability of cells after separation was found to be greater that 94% as determined by trypan blue exclusion.
  • these data support the conclusion that a population of germ-line competent cells exists in the central region of the stage X (E-G&K) embryo and that the germ-line competent cells can be isolated using a technique such as magnetically activated cell sorting using antibodies such as EMA-1 that recognize epitopes that are specifically expressed by germ-line competent cells.
  • Table 1 Mean age and the range in age at the onset of egg production and fertility of hens derived from Stage X embryos that were irradiated or from which approximately 500 cells were extirpated.
  • Table 2 Mean concentration of spermatozoa and fertility of males derived from Stage X embryos that were irradiated or from which approximately 500 cells were extirpated.
  • Irradiation Lateral Central Number Mean concentration (10 9 Mean % Fertility (100 x removal removal of males cells/ml) of spermatozoa number of chicks of cells of cells and range in parentheses hatched/number of eggs set) and range in parentheses
  • Rates of somatic chimerism expressed as the % of black pigmentation in plumage and the rate of germ-line transmission expressed as the number of donor-de ⁇ ved offsp ⁇ ng/total number of offsp ⁇ ng from chimeras derived from Stage X embryos that were irradiated or from which approximately 500 cells were extirpated.
  • FIG. 1 The structure of an embryo at the time of laying illustrated as a cross-section through the embryo perpendicular to the surface of the yolk. At this time, the embryo contains 40,000-60,000 cells and is referred to as a Stage X embryo.
  • FIG. 1 Phase contrast illumination micrograph of a microscopic field illustrating die expression of EMA-1 epitopes on stage X blastodermal cells cultured 18 hours with SNL feeder cells (magnification 300x).
  • Figure 3 Fluorescence micrograph of the same microscopic field as figure 2 illustrating the expression of EMA-1 epitopes on stage X blastodermal cells cultured 18 hours with SNL feeder cells (magnification 300x).
  • Figure 4 Phase contrast illumination micrograph a microscopic field illustrating the expression of SSEA-1 epitopes after 18 hours in culture.
  • FIG. 1 Fluorescence micrograph of the same microscopic field as figure 4 illustrating the expression of SSEA-1 epitopes after 18 hours in culture. Note the variation in fluorescence intensity.
  • FIG. Phase contrast illumination micrograph of a microscopic field illustrating the SSEA-1 expression on stage X whole mount (magnification 300X).
  • Figure 7 Fluorescence micrographs of the same microscopic field as figure 1 illustrating the SSEA-1 expression on stage X whole mount (magnification 300X).
  • Figure 8 Phase contrast illumination micrograph of a microscopic field illustrating HNK- 1/NC-l expression on stage X blastodermal cells after 18 hours in culture.
  • Figure 9 Fluorescent micrograph of the same microscopic field as figure 8 illustrating HNK-l/NC-1 expression on stage X blastodermal cells after 18 hours in culture.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

On décrit des procédés de sélection de cellules compétentes de lignées germinales dans des embryons de poulets en phase X(E-G & K); ces procédés consistent à sélectionner des cellules dans des embryons de poulets en phase X(E-G & K) qui ont un épitopes exprimé par des cellules compétentes de lignées germinales associées à leur surface cellulaire. L'épitope peut être EMA-1 ou SSEA-1, par exemple. On décrit également des procédés de production d'un embryon de poulet chimère et d'un poulet chimère dans lesquels on utilise les cellules compétentes de lignées germinales sélectionnées.
PCT/CA1998/000145 1997-02-28 1998-02-27 Procedes de selection de cellules competentes de lignees germinales dans des embryons de poulets et utilisation de ces cellules dans la production de chimeres WO1998038283A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU60848/98A AU6084898A (en) 1997-02-28 1998-02-27 Methods for selecting germ-line competent cells in chicken embryos, and the use of the cells in the production of chimeras
JP53710598A JP2001516206A (ja) 1997-02-28 1998-02-27 ニワトリ胚で生殖系列コンピテント細胞を選択する方法およびキメラの産生における該細胞の使用
CA002282791A CA2282791A1 (fr) 1997-02-28 1998-02-27 Procedes de selection de cellules competentes de lignees germinales dans des embryons de poulets et utilisation de ces cellules dans la production de chimeres
EP98905172A EP0973870A1 (fr) 1997-02-28 1998-02-27 Procedes de selection de cellules competentes de lignees germinales dans des embryons de poulets et utilisation de ces cellules dans la production de chimeres

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3948897P 1997-02-28 1997-02-28
US60/039,488 1997-02-28

Publications (1)

Publication Number Publication Date
WO1998038283A1 true WO1998038283A1 (fr) 1998-09-03

Family

ID=21905744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1998/000145 WO1998038283A1 (fr) 1997-02-28 1998-02-27 Procedes de selection de cellules competentes de lignees germinales dans des embryons de poulets et utilisation de ces cellules dans la production de chimeres

Country Status (5)

Country Link
EP (1) EP0973870A1 (fr)
JP (1) JP2001516206A (fr)
AU (1) AU6084898A (fr)
CA (1) CA2282791A1 (fr)
WO (1) WO1998038283A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001011018A2 (fr) * 1999-08-11 2001-02-15 Wisconsin Alumni Research Foundation Lignees cellulaire blastodermique aviennes
FR2832423A1 (fr) * 2001-11-22 2003-05-23 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
EP1590435A2 (fr) * 2003-01-16 2005-11-02 North Carolina State University Depletion de cellules germinales embryonnaires endogenes dans des espaces aviaires
FR2898909A1 (fr) * 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Combinaison de marqueurs de cellules aviaires
ES2531727A1 (es) * 2014-11-14 2015-03-18 Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia) Métodos de eliminación celular

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710439A2 (fr) * 1994-10-31 1996-05-08 Director Of National Institute Of Animal Industry, Ministry Of Agriculture, Forestry And Fisheries Procédé de cryoconservation de cellules germinales primordiales et cellules germinales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710439A2 (fr) * 1994-10-31 1996-05-08 Director Of National Institute Of Animal Industry, Ministry Of Agriculture, Forestry And Fisheries Procédé de cryoconservation de cellules germinales primordiales et cellules germinales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ETCHES, R.J. ET AL.: "Chimeric chickens and their use in manipulation of the chicken genome", POULTRY SCIENCE, vol. 72, 1993, pages 882 - 889, XP002069539 *
KARAGENÇ, L. ET AL.: "Origin of primordial germ cells in the prestreak chick embryo", DEVELOPMENTAL GENETICS, vol. 19, 1996, pages 290 - 301, XP002069538 *
PETITTE, J.N. & KARAGENÇ, L.: "growth factors during early events in avian embryo development", POULTRY AND AVIAN BIOLOGY REVIEWS, vol. 7, no. 2/3, 1996, pages 75 - 87, XP002069537 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001011018A2 (fr) * 1999-08-11 2001-02-15 Wisconsin Alumni Research Foundation Lignees cellulaire blastodermique aviennes
WO2001011018A3 (fr) * 1999-08-11 2001-07-05 Wisconsin Alumni Res Found Lignees cellulaire blastodermique aviennes
FR2832423A1 (fr) * 2001-11-22 2003-05-23 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
WO2003043415A1 (fr) * 2001-11-22 2003-05-30 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
EP1590435A2 (fr) * 2003-01-16 2005-11-02 North Carolina State University Depletion de cellules germinales embryonnaires endogenes dans des espaces aviaires
EP1590435A4 (fr) * 2003-01-16 2006-08-02 Univ North Carolina State Depletion de cellules germinales embryonnaires endogenes dans des espaces aviaires
US7994388B2 (en) 2003-01-16 2011-08-09 North Carolina State University Depletion of endogenous primordial germ cells in avian species
FR2898909A1 (fr) * 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Combinaison de marqueurs de cellules aviaires
WO2007110343A3 (fr) * 2006-03-24 2007-11-29 Agronomique Inst Nat Rech Combinaison de marqueurs de cellules aviaires
ES2531727A1 (es) * 2014-11-14 2015-03-18 Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia) Métodos de eliminación celular

Also Published As

Publication number Publication date
CA2282791A1 (fr) 1998-09-03
JP2001516206A (ja) 2001-09-25
AU6084898A (en) 1998-09-18
EP0973870A1 (fr) 2000-01-26

Similar Documents

Publication Publication Date Title
US6331406B1 (en) Human enbryonic germ cell and methods of use
US6090622A (en) Human embryonic pluripotent germ cells
Radtke et al. Remyelination of the nonhuman primate spinal cord by transplantation of H-transferase transgenic adult pig olfactory ensheathing cells
CN100379857C (zh) 嵌合体动物及其制备方法
AU722913B2 (en) Method for identifying sex specific and species specific molecules, molecules identified using the method, and uses of the molecules
JP2006519015A (ja) 幹細胞を単離または生成するためのマーカーとしてのＩｓｌｅｔ１の使用
JP2003517261A (ja) Ｐｇｃの長期間培養によるトリの胚生殖（ｅｇ）細胞系の産生、クローン形成およびキメラ形成へのその利用
Ono et al. Immunomagnetic purification of viable primordial germ cells of Japanese quail (Coturnix japonica)
AU2001251311B2 (en) Human mullerian duct-derived epithelial cells and methods of isolation and uses thereof
AU2003219764B2 (en) Human fetal bladder-derived epithelial cells
JP2001514751A (ja) 胎児診断方法
WO1998038283A1 (fr) Procedes de selection de cellules competentes de lignees germinales dans des embryons de poulets et utilisation de ces cellules dans la production de chimeres
JP2003516134A (ja) 性染色体特異的タンパク質、種特異的および精子特異的タンパク質、ならびにそれらの同定および単離の方法
US6987024B1 (en) Human ovarian mesothelial cells and methods of isolation and uses thereof
AU2001253343A1 (en) Human ovarian mesothelial cells and methods of isolation and uses thereof
Lee et al. Developmental studies of sperm surface antigens using sperm-specific monoclonal antibodies
Nel-Themaat et al. Cloned embryos from semen. Part 1: in vitro proliferation of epithelial cells on embryonic fibroblasts after isolation from semen by gradient centrifugation
Græm et al. Blood group substances, T6 antigen and heterochromatin pattern as species markers in the nude mouse/human skin model
Jancsovics The influence of embryonic testosterone treatment on bursal mesenchymal environment
JP3171391B2 (ja) モノまたはポリクローナル抗体、およびその抗体を用いた魚卵の種の判定方法
Whitten et al. Clomiphene Citrate is Successful in Select Cases Of Male Hypogonadotropic Hypogonadism
Xin et al. Colloquium Paper: Regenerative Medicine: In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme
US20020037494A1 (en) Method for identifying sex specific and species specific molecules, molecules identified using the method, and uses of the molecules
MXPA99008933A (es) Linea de celulas germinales embrionicas, humanas y metodos de uso
JP2007129991A (ja) 哺乳動物のａ型（未分化型）精祖細胞の同定、分離及び／又は回収方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1998 537105

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2282791

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2282791

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1998905172

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998905172

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998905172

Country of ref document: EP